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ABSTRACT
Recently, the FDA has encouraged testing of medications
among pediatric patients during drug development. Phar-
maceutical companies have responded by conducting
more clinical trials among children, and researchers are
becoming aware of the unique challenges of assessing
pediatric health outcomes, including health-related qual-
ity of life (HRQL). Like adults, children experience effects
of illness and treatment beyond physiologic outcomes.
Further pediatric HRQL research is necessary to examine
these broader psychosocial outcomes and provide a thor-
ough understanding of the effects of treatment on chil-
dren’s health status. The purpose of the current review is
to discuss key regulatory and methodologic developments
and provide guidance for future research on pediatric
HRQL. This review of pediatric HRQL assessment
includes ﬁve sections: 1) recent pediatric regulatory devel-
opments in the United States; 2) issues in deﬁning and
conceptualizing pediatric HRQL, including the impor-
tance of contextual variables such as family and peer sys-
tems; 3) methodologic issues (e.g., the proxy question,
developmental differences, response sets) with recommen-
dations for addressing these issues in clinical trials; 4) val-
idated generic and condition-speciﬁc pediatric HRQL
measures; and 5) a recommendation for additional
research on the HRQL impact of childhood psychiatric
disorders. It is advocated that assessment of HRQL
among children should be conducted regularly as an inte-
gral part of drug development.
Keywords: health-related quality of life, quality of life,
pediatric, children, regulatory, assessment.
Introduction
Historically, drug testing has not frequently been
conducted among pediatric samples, possibly
because of the added complexities of engaging
children as subjects in medical research. Without
controlled pediatric clinical trials, physicians and
parents have remained uncertain about many drug
treatment outcomes in this population. Thus, the
FDA has recently issued a series of regulations to
encourage pediatric drug testing as an integral part
of drug development.
Pharmaceutical companies have responded to
these regulations by conducting more clinical trials
with pediatric samples. These pediatric trials have
focused primarily on efﬁcacy and safety end points,
whereas relatively little research has examined the
impact of drug treatment on children’s health-
related quality of life (HRQL). Like adults, chil-
dren experience impacts of illness and treatment
beyond the purely medical effects. More research
on HRQL among children is necessary to identify
these broader outcomes and provide a thorough
understanding of children’s health status. Con-
sequently, a small but growing body of research
has  examined  pediatric  HRQL,  and  researchers
are  becoming  more  aware  of  the  unique
challenges involved in assessing HRQL among
children.
The purpose of the current review is to discuss
key regulatory and methodological developments
and provide guidance for future research on pediat-
ric HRQL. This review includes ﬁve sections: 1)
recent pediatric regulatory developments in the
United States; 2) deﬁnition and conceptualization of
pediatric HRQL; 3) methodologic issues relating to
the measurement of pediatric HRQL with recom-
mendations for addressing these issues in clinical
trials;  4)  generic  and  condition-speciﬁc  measures
of pediatric HRQL; and 5) a recommendation for
future research on the HRQL impact of psychiatric
disorders in children.
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Review of Pediatric-Speciﬁc Regulatory 
Developments in the United States
In recent years, several regulations have been intro-
duced with the intent to encourage pharmaceutical
companies to conduct pediatric clinical trials. The
Pediatric Exclusivity Provision, which was part of
the FDA Modernization Act (FDAMA) of 1997,
provided a signiﬁcant ﬁnancial incentive for phar-
maceutical companies who conducted drug testing
among children [1,2]. This provision required the
Food and Drug Administration (FDA) to create and
annually update a list of drugs for which additional
pediatric research may lead to improved treatment
outcomes for children. The FDA requests pediatric
studies for drugs on this list, and if a pharmaceutical
company responds by conducting a study according
to acceptable scientiﬁc standards, then the company
is given 6 additional months of market exclusivity
for this drug. The FDA can also request pediatric
studies for drugs that are not on the priority list,
and pharmaceutical companies are permitted to ask
the FDA to issue a written request for a study pro-
posal. The Exclusivity Provision, which was origi-
nally intended to apply for only 5 years beginning in
1997, was extended for an additional 5 years by the
Senate and House of Representatives as part of the
Best Pharmaceuticals for Children Act.
The Pediatric Rule [3] followed the FDAMA of
1997. This gave the FDA the authority to compel
companies to conduct pediatric research for new
and marketed drugs and biologic products that are
intended for children. Speciﬁcally, the rule required
that studies be conducted: 1) for drugs used to
treat substantial numbers of children; 2) for drugs
that could offer therapeutic beneﬁts to children;
and 3) if the absence of adequate testing and labe-
ling for children could pose signiﬁcant risk [1,2]. In
2000, the updated FDA Pediatric Rule required
manufacturers to include pediatric data in applica-
tions for new drugs as well as applications to
extend indications for drugs expected to be used
substantially in children, deﬁned as at least 50,000
uses of the drug in the entire pediatric population
[2]. The Pediatric Rule was temporarily suspended
in March 2002, before being reinstated 1 month
later [4,5].
The dramatic increase in pediatric drug testing
since 1997 suggests that these regulations have been
successful. Prior to the Exclusivity Provision and the
Pediatric Rule, the FDA requested few pediatric
studies, and pharmaceutical companies completed
even fewer. Drug companies promised to conduct
71 postmarketing pediatric clinical trials between
1991 and 1996, but only 11 were completed [6]. As
of April 2002, however, pharmaceutical companies
had submitted 303 proposed study requests, the
FDA had issued 237 written requests, and 54 drugs
had received the 6-month exclusivity extension
[7,8].
Conceptualizing Pediatric Health-Related 
Quality of Life
Deﬁning Pediatric HRQL
Deﬁnitions of HRQL vary widely, but there are two
central aspects of this construct that are inherent in
most deﬁnitions [9–11]. First, HRQL is subjective,
and therefore, it should be assessed from the
patient’s perspective whenever possible. Second,
HRQL is a multidimensional construct that inte-
grates a broad range of outcomes. One deﬁnition
from the adult health outcomes literature that
includes both of these components describes HRQL
as an individual’s subjective perception of the
impact of health status, including disease and treat-
ment, on physical, psychologic, and social function-
ing [12]. Although this general deﬁnition also
applies to HRQL of children, the speciﬁc aspects of
a child’s life that comprise these three domains of
functioning are different. Thus, when designing a
pediatric HRQL instrument, it is important to
ensure that items correspond to experiences, activ-
ities, and contexts that are directly relevant to the
age of the sample.
The Central Role of  Context in Child Development and 
Pediatric HRQL
When assessing children’s social and psychological
functioning, it is particularly important to remem-
ber that children are embedded within multiple
social contexts including the family, the child’s peer
group, the classroom, and the community [13].
Each of these contexts is likely to contribute to
HRQL and mediate the impact of disease and treat-
ment on the child. For example, asthma is a disease
that has been shown to impair HRQL in adults and
children [14], but the speciﬁc effects of asthma are
likely to be different for children because of their
context. Asthma could limit a child’s participation
in play and athletics with peers, leading to social
and emotional consequences that are different from
those experienced by adults with the same disease.
Thus, instruments designed to assess HRQL among
children with asthma must assess child functioning
within the relevant contexts. One such instrument
is the Pediatric Asthma Quality of Life Question-
naire, which refers to typical child contexts such as
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playing at recess, playing with friends, and riding a
bicycle [15].
Developmental theorists have often asserted that
the relationship between children and their social
context is complex, involving simultaneous mutual
inﬂuence among children and multiple contexts
[13,16]. According to this theoretical perspective,
children are active agents exerting an inﬂuence
upon their context while simultaneously being
shaped by their context. This bidirectional inﬂuence
has been demonstrated by empirical research on
parent–child interaction, in which children and par-
ents have been observed to mutually inﬂuence each
other’s behavior [17,18]. Furthermore, children’s
functioning and behavior within their multiple
social contexts are linked. For example, children’s
experiences within the family have been shown
to contribute to their behavior, social cognition,
friendship patterns, and level of acceptance from
peers [19–22]. Researchers have suggested that
characteristics of these contextual factors, such as
families, peer relationships, local health clinics, and
neighborhoods, should be included in assessment
and analysis of pediatric health outcomes and qual-
ity of life [23,24].
There are two reasons that context is qualita-
tively different for children than for adults. First,
contextual factors have been shown to have a long-
term inﬂuence on children’s social and psychologic
development. For example, peer rejection in child-
hood is associated with numerous long-term nega-
tive outcomes including delinquency and school
dropout [25]. Second, children have less power than
adults to make signiﬁcant changes to their context.
Adults who have adequate ﬁnancial resources or
social support can leave a problematic workplace or
a dysfunctional marriage. In contrast, children typ-
ically do not have the option of signiﬁcantly chang-
ing a problematic environment.
In sum, context plays a different and possibly
more important role for children than for adults,
and children’s quality of life depends on complex
interactions between the child and multiple social
contexts. Assessment of pediatric HRQL must con-
sider these contextual variables such as family func-
tioning, relationships with peers, and community
factors. Furthermore, because the impact of disease
and treatment may be substantially different for
adults and children, HRQL outcomes from clinical
trials with adults cannot be applied to children. It
is therefore necessary to directly examine HRQL
among children, rather than estimating pediatric
HRQL outcomes based on research with adult
samples.
Why Pediatric HRQL Research Is Necessary
Although pediatric clinical trials focus primarily on
efﬁcacy and safety, there is growing consensus that
assessment of HRQL outcomes is also necessary to
provide a complete picture of children’s health sta-
tus [11,26,27]. Conceptually, HRQL instruments
are designed to assess a broader range of children’s
day-to-day functioning than clinical measures, and
empirical ﬁndings suggest that HRQL measures
provide unique information beyond clinical symp-
toms. For example, HRQL has been shown to be
only moderately correlated with measures of symp-
tom severity in studies of pediatric asthma [14,15],
indicating that HRQL and clinical symptoms are
related, but distinct from each other. Thus, HRQL
instruments can be included in clinical trials as a
complement to the traditional clinical measures of
efﬁcacy and safety. In combination, HRQL and clin-
ical measures can provide a complete assessment of
the impact of disease and treatment on children’s
overall well-being. Research that incorporates this
comprehensive perspective can be used to inform
pediatric health policy, treatment guidelines, and
treatment of individual children.
Methodological Issues in Pediatric 
HRQL Assessment
This section reviews ﬁve methodological issues that
must be considered when designing a measure or a
study of pediatric HRQL. In each of the ﬁve areas,
relevant empirical research is discussed, and practi-
cal recommendations are offered.
The Youngest Age at Which Children Can 
Report their HRQL
Researchers have made recommendations regarding
the youngest age at which children can reliably
report their health status and HRQL. Opinions
vary, but it is generally estimated that children
can  begin  reporting  the  more  concrete  domains
of their own HRQL between 4 and 6 years old
[14,28,29]. Self-report HRQL instruments have
been designed and psychometrically validated for
children in this young age range, including the Pedi-
atric Rhinoconjunctivitis Quality of Life Question-
naire (PRQLQ; ages 6–12) [30] and the Childhood
Asthma Questionnaire—Form A (CAQA; ages 4–7)
[31].
Prior research has identiﬁed several characteris-
tics that should be considered when determining
the lower age cutoffs for a questionnaire assessing
HRQL. In a review of pediatric health outcomes lit-
erature, Landgraf and Abetz [32] indicated that
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there are age-related differences in the type of health
concepts that children can comprehend. They
report that children as young as age 5 can provide
empirically reliable reports on concrete health con-
cepts such as pain and medication use. In contrast,
questionnaires that assess relatively subjective or
abstract domains of HRQL, such as the emotional
impact of illness, will likely be appropriate for older
children.
The level of language comprehension may also
place a lower limit on the age appropriateness of
a questionnaire. A study that assessed children’s
understanding of health-related terms found that
only 57% of 5-year-old children had a good under-
standing of the word “nervous” [33]. By age 8, all
children in the sample understood this term (see
Fig. 1) [33]. When designing self-administered
paper-and-pencil questionnaires, it is also essential
to consider the typical reading levels of children in
the intended age range [32–34].
In sum, children as young as age 4 can often pro-
vide some information on concrete aspects of their
health status. Assessment of more subjective HRQL
domains may require a somewhat older sample. The
reliability and validity of data provided by children
depends on the complexity of the constructs and
terminology used. The lower age limit will also vary
according to individual differences in children’s
cognitive skills and their understanding of health
status.
There are several ways to address this issue when
assessing health status and HRQL in pediatric clin-
ical trials. First, when developing a questionnaire, it
is necessary to conduct pilot testing and careful cog-
nitive debrieﬁng with children of different ages in
order to determine the lower age limit at which chil-
dren can understand the questions and provide reli-
able and valid responses. Second, when determining
the lower age limit of a clinical trial sample, it will
be necessary to consider the disease area, the antic-
ipated effects of the drug being tested, and the type
of domains to be assessed. If the primary interest is
in the drug’s impact on physical domains, the trial
can include self-report instruments designed for
younger children. If the drug is expected to improve
psychological  or  social  domains  of  HRQL,  it  will
be necessary to assess older children or use proxy
reporters for younger children (see discussion of
proxy issue later in this article). Third, because
greater variability is expected with younger children
due to measurement error, a larger sample size will
be required to detect treatment effects.
The Proxy Question
There is substantial debate in the pediatric health
outcomes literature concerning who is the most
appropriate respondent when assessing children’s
HRQL [27]. Some researchers advocate questioning
the child directly, whereas others prefer to use a par-
ent or primary caregiver as a proxy respondent.
Studies have examined this question by assessing
the degree of agreement between parent and child
report. The guiding assumption of these studies is
that a high level of agreement would indicate that
either the child or the parent could be used as the
respondent without compromising validity of the
HRQL assessment. In the case of disagreement,
however, researchers would need to determine
whose report is more reliable or appropriate for
subsequent studies.
Empirical investigations of agreement between
parent and child report of the child’s health status
and HRQL have yielded mixed results. Some
studies report high parent–child agreement [32],
whereas others have found low agreement [35]. The
degree of agreement may depend on several factors,
including the domain that is assessed. For example,
correlations between parent and child report have
been shown to be higher for observable physical
domains than nonobservable emotional domains
[27]. Studies that have considered the child’s age
have not reported consistent results. Some studies
have found that older age was associated with
greater parent–child agreement [36], whereas other
Figure 1 Age-related differences in children’s understanding of  the
term “nervous” [33].
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investigations have reported either the opposite [37]
or no signiﬁcant age effects [27]. Similarly, research
examining the impact of the child’s health on par-
ent–child agreement has yielded conﬂicting infor-
mation. Several studies have found greater parent–
child agreement for sick children [27], whereas oth-
ers have found greater agreement between parents
and healthy children [38]. One study reported that
children provide lower estimates of HRQL than
their parents [39], but this has not been consistently
replicated [27]. In sum, agreement between parent
and child report of HRQL varies considerably, and
further research is needed to clarify the factors that
may inﬂuence this level of agreement.
Given these conﬂicting results, it is not yet pos-
sible to provide an empirically based, conclusive
answer to the proxy question. There are three
options for addressing the proxy issue when devel-
oping a measure of pediatric HRQL, and each has
advantages and disadvantages that must be weighed
when designing a study. Whenever a child is able to
provide reliable and valid data, the child’s self-
report is the ideal strategy because it is consistent
with the deﬁnition of HRQL, which emphasizes the
patient’s subjective perspective. Furthermore, it is
important to consider the child’s perceptions to pro-
vide treatments that will have the most positive
impact in multiple domains, including contexts that
may be unknown to parents such as school or day-
care [10].
The disadvantage of child-report instruments is
that children, particularly at younger ages, may not
be able to provide reliable information on complex
or abstract health-related constructs. Thus, before
implementing a child-report HRQL measure,
researchers will need to evaluate the age appropri-
ateness of the instrument, including the vocabulary,
instructions, sentence structure, content, and
response options. If the researchers believe that it is
essential to assess the subjective views of younger
children, but they are concerned about develop-
mental limitations, one option is to develop an
interviewer-administered instrument. A structured
interview can include standardized procedures for
teaching children how to respond to the measure,
instructing children not to answer questions they
do not understand, and checking children’s com-
prehension of items. Although an interviewer-
administered instrument will be more costly to use
than a self-report questionnaire, structured inter-
view methodology may help younger children pro-
vide more reliable and valid data.
For assessment of more complex constructs, it
may be necessary to use an adult as a proxy
respondent. In comparison to children, adults
can generally be expected to provide more relia-
ble information on more complex, abstract, psy-
chologically oriented concepts. Parents are the
most common proxy respondents, and there is
evidence suggesting that parent reports are more
accurate than those given by physicians or nurses
[40]. For very young or severely disabled chil-
dren, parents may provide valuable information
that would otherwise be unobtainable. In addi-
tion, the parent’s perspective is important in itself
because of the dependent nature of the parent–
child relationship. It is the parent who typically
assesses the impact of the child’s health and
decides whether the child will receive treatment.
The parent can also provide valuable information
on the impact of the child’s illness and treatment
on family functioning, which is an integral part of
children’s HRQL.
There are several disadvantages of using parents
as proxy respondents. First, a proxy report is
somewhat inconsistent with the concept of HRQL,
which is deﬁned according to the patient’s subjec-
tive view. Thus, it may be theoretically sound to
have parents report on a child’s “health status,”
but not speciﬁcally on a child’s HRQL. Second,
the proxy method raises questions concerning
which parent to use and whether mother and
father reports can be considered equivalent [9,32].
In longitudinal trials with parent proxies, it is
recommended that the same parent provide the
reports across the study to avoid systematic error
resulting from differences between the two par-
ents. Third, it is likely that parents’ reports of a
disease’s impact on their children will be biased by
how the parents themselves are affected. Finally, it
is not always clear whether parents are the most
appropriate adult proxy respondent [32]. Some
children may spend more time with a teacher, day-
care provider, or other family member than with a
parent, and this other adult may have more accu-
rate insight into the child’s social and psychologi-
cal functioning.
Because neither the child’s self-report nor the
parent’s proxy report is without risk, some
researchers have suggested obtaining information
from both the child and a parent [27,29]. This
approach may provide the most complete picture of
how a disease or treatment impacts the lives of chil-
dren and their families. Nevertheless, it will be more
costly to collect data from both sets of respondents
rather than choosing one, and this strategy raises
several methodological questions. For example,
researchers will have to decide whether to pool data
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from the two respondents or interpret their data
separately. Another potential problem is the ques-
tion of how to interpret ﬁndings when parents and
children’s reports diverge. It is difﬁcult to determine
whose reports are more accurate because parent
report may be expected to have greater reliability,
but child report may have more validity given the
subjective nature of HRQL. One possible approach
in a clinical trial is to assess both child and parent
reports, but to determine a priori that one will be
the primary HRQL endpoint of a clinical trial. For
younger children, it may be best to choose parent
report as the primary endpoint, but also assess the
child’s self-report which can provide additional
information on HRQL.
In conclusion, there is not a solution to the proxy
question that will be correct for every clinical trial.
Consequently, it is recommended that researchers
carefully examine the costs and beneﬁts of each pos-
sible approach during instrument development,
before pivotal studies. The decision of whether to
use child-report, parent-report, or both requires
consideration of numerous factors including the
child’s age, the domains of HRQL that may be
addressed, the disease area, the study design, and
the intended use of the data.
Age-Appropriate Instrument Formatting and Design
Several previous reviews of pediatric health out-
comes assessment have discussed aspects of instru-
ment formatting and design that can be adjusted
depending on the age of the respondents
[10,11,28,29,32,41,42]. The speciﬁc design and
format of each pediatric HRQL instrument will
depend on numerous factors including the con-
tent of the items and the ages of the intended
respondents. Thus, it is recommended that instru-
ments be pilot tested so that formatting and
administration procedures can be evaluated before
using the measure with a large sample. Cognitive
debrieﬁngs, in which children are asked to com-
ment on instruments, can also provide important
information regarding the age appropriateness of
items before using an instrument in pivotal stud-
ies [43,44]. The following are ﬁve issues to con-
sider when developing a measure of pediatric
HRQL.
Likert scales. There are developmental differences
in children’s ability to understand and respond to
items rated on Likert scales. Eight-year-old children
have been shown to accurately use the full range of
5- and 7-point Likert scales to rate their health
status, whereas younger children tend to use more
extreme responses [33,45]. When using Likert
scales with younger children, the response options
can be creatively designed to help them understand
the task. For example, circles of graduated sizes and
illustrations to anchor the extreme responses can be
used as visual aids, as demonstrated in Figure 2
[33].
Recall periods. Age-related differences have also
been demonstrated in children’s ability to accu-
rately report on their health status within a speciﬁc
recall period. Eight-year-old children have been
shown to use a 4-week recall period with reasona-
ble accuracy, but younger children may have difﬁ-
culty with the concept of 1 week or 1 month
[33,45]. One strategy for helping younger children
understand this task is to tie the recall period to a
concrete event that they would remember [45]. For
example, children can be asked to rate their health
status since their last doctor’s appointment 1 week
ago.
Length of the instrument. The length of a ques-
tionnaire or interview for children requires care-
ful consideration and pilot testing because of the
wide variation in children’s ability to maintain
attention to tasks. Generally, older children can be
expected to complete longer measures than
younger children.
Children’s degree of independence during admini-
stration. It may be necessary to adjust administra-
tion procedures for different ages. Younger children
may require interviewers to assist them with reading
questionnaires, understanding administration pro-
cedures, and staying focused on the task. Older
children can be expected to complete written ques-
tionnaires with greater independence.
Formatting details. When designing child-report
measures, it is particularly important to attend to
details of formatting, such as maintaining a clear
layout of items and using larger print for younger
children.
Figure 2 Response options with anchoring illustrations from the
Child Health and Illness Proﬁle (CHIP) [33].
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Creating Multiple Forms of  a Measure Corresponding 
to Different Age Groups
Bibace and Walsh [46] demonstrated that children’s
understanding of illness develops in stages consist-
ent with Piaget’s theory of cognitive development.
Piaget proposed that children’s causal reasoning is
guided by logic different from that of adults, and
this logic develops in a series of sequentially ordered
stages [47]. By applying this theory, Bibace and
Walsh derived and tested stages for children’s con-
ceptions of illness, beginning with early prelogical
stages typical of children between 2 and 6 years old
who are unable to explain the causes of illness.
By approximately 11 years of age, many children
have progressed to formal-logical thinking, which
is characterized by a conception of the causal
sequence of physiological mechanisms. In the ﬁnal
stage, children demonstrate an understanding that a
person’s thoughts and feelings can affect physical
functioning. This research was intended to help
physicians and health educators communicate more
effectively with children, and the ﬁndings have pro-
vided a theoretical and empirical foundation for
health education curricula on AIDS/HIV and smok-
ing [48–50]. This work on children’s conceptions of
illness can also be applied to measure development
for clinical trials in which children are asked to
report their health and HRQL.
One strategy for addressing these developmental
differences is to create multiple forms of a child-
report instrument, each designed for a different
age group. When designing multiple forms, a
researcher will need to determine appropriate age
groupings and ways that the forms will differ from
each other. An example of an instrument that uses
this multiple form approach is the Childhood
Asthma Questionnaire (CAQ) [31,51]. This meas-
ure was designed to evaluate treatments by assess-
ing children’s feelings about their everyday lives
and their asthma. Three child-report forms were
developed, intended for children ages 4 to 7, 8 to
11, and 12 to 16 (see Table 1). Forms for older age
ranges are longer with more response options and
more complex HRQL domains. For example,
Form C (ages 12 to 16) is speciﬁcally designed to
correspond to the abilities, interests, and social
relationships of adolescents.
The advantage of this multiple form approach is
that it takes into account children’s developmental
differences, including their conception of illness as
well as its cause and impact. With this strategy, it is
possible to design a series of questionnaires that
assess the same general constructs, while ensuring
that formatting and content are age appropriate for
all children. Nevertheless, this approach also raises
some methodological and practical challenges. For
example, because the forms contain different items
and domains, data cannot be pooled across age
groups. If analyses are conducted separately for the
different age groups, it will be necessary to collect a
sample that is large enough to ensure sufﬁcient
statistical power for each age group. Before devel-
oping or using multiple forms of an instrument,
researchers will need to evaluate whether they have
sufﬁcient time and ﬁnancial resources for the addi-
tional data collection and analyses that will be
required.
Avoiding Child Response Sets
When responding to questionnaires or interviews,
children may have a proclivity for a response set,
which is a tendency to provide a certain type of
response regardless of the question. Response sets
are problematic because they can cause data to be
biased, skewed, or simply inaccurate. Consequently,
response sets can introduce systematic error into the
data that may mask meaningful or statistically sig-
niﬁcant ﬁndings.
Examples of response sets that are believed to be
more common among children than adults include
responding with the intent to please the interviewer
or answering questions they do not understand in
an attempt to appear competent [10,29]. In addi-
tion, some children may have a tendency to provide
repetitive responses (e.g., consistently choosing the
same number on a scale), particularly when a meas-
ure repeatedly uses the same scaling system [29]. A
common child response set with demonstrated
developmental differences is the tendency to pro-
vide extreme answers (e.g., responding only with 1
or 5 on a series of 5-point Likert scales), which is
primarily a risk with younger children. Children
ages 5 to 6 have been shown to provide signiﬁcantly
more extreme responses than children ages 7 to 8
when using a Likert scale [33].
Response sets can be minimized through careful
instrument development and study design. One
strategy is to assess some constructs twice within a
single measure, once with a positively voiced item
and once with a negatively voiced item (e.g., “I have
been sick during the past 2 weeks” and “I have been
healthy during the past 2 weeks”). Children who
answer with repetitive response sets may be identi-
ﬁed if they provide contradictory answers to the
two items. Similarly, HRQL can be assessed with
more than one instrument in a given study, possibly
using both a generic and a disease-speciﬁc measure.
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Correlations between similar scales on the two
measures can then be used to detect inconsistent
reporting. When designing a pediatric study, it is
also important to consider the length and number
of measures. Younger children, in particular, may
begin to rely on response sets and provide inaccu-
rate responses if the length of an assessment exceeds
their attention span or patience.
During data collection, project staff can be
trained to recognize common child response
sets. These staff members should review children’s
responses following independent questionnaire
completion and carefully consider children’s
responses during interviews. Then, instances in
which the child appears unwilling or unable to
respond correctly should be documented. This doc-
umentation can provide justiﬁcation for excluding
the participant’s data in the analyses.
During data analysis, it is important to remain
aware that some children’s data may reﬂect re-
sponse sets. Examination of scatter plots and fre-
quency tables is often helpful in detecting children
who have provided invalid data. If there is sufﬁcient
evidence that a child did not respond accurately, this
child can be considered an “outlier,” and it will be
preferable to exclude these data from the analyses
(for outlier criteria, see Bollen and Jackman [52]
and Neter et al. [53]).
For phase III and IV clinical trials, criteria for
identifying these outliers should be speciﬁed a pri-
ori based on experience with the instrument during
instrument development and earlier phase trials.
During these earlier studies, it may be possible to
identify the common response sets for a given
measure, the ages at which children are most likely
to respond inaccurately, and an expected percent-
age of children that may have these difﬁculties. If a
substantial number of children are expected to
demonstrate response sets, researchers can over-
sample to ensure sufﬁcient sample size and statisti-
cal power after outliers are dropped from the
analysis data set.
Selected Generic and Condition-Speciﬁc 
HRQL Measures for Use in Pediatric 
Populations
Both generic and condition-speciﬁc measures have
been developed to assess HRQL in children (for
thorough reviews of existing measures, see Eiser
and Morse [9,54]). As is true for adults, generic
measures are useful to compare HRQL across var-
ious populations, which may include patients who
vary in terms of their medical conditions. Conse-
quently, generic measures can be used to compare
the HRQL impact of various diseases. In addition,
data from patients with a speciﬁc disease can be
compared to general pediatric population norms to
determine the impact of the disease on HRQL. For
example, normative data for the Child Health
Questionnaire are available, including norms for
groups divided by age, sex, and medical conditions.
Generic measures have been developed for children
from 0 to 18 years old, using both parent and child
report (see Table 2 for a selection of Generic HRQL
measures) [35,39,55–62].
Condition-speciﬁc measures take into account
aspects of disease and treatment that are relevant to
speciﬁc medical conditions. Compared to generic
measures, these measures tend to be more sensitive
to changes, and they may be more effective at
detecting treatment effects. Therefore, they are
often used in clinical trials. Condition-speciﬁc pedi-
atric measures are available for a number of medical
conditions, such as asthma, allergic rhinitis, cancer,
diabetes, epilepsy, juvenile arthritis, Crohn’s dis-
ease, and spina biﬁda (see Table 3 for a selection
of disease-speciﬁc HRQL measures) [15,31,51,63–
71]. Only one condition-speciﬁc HRQL measure
was located that was developed for a psychiatric
disorder in children (the ADHD Impact Module)
[72].
Recommendation for Future Research: 
The Impact of Psychiatric Disorders on 
Pediatric HRQL
To date, research on pediatric HRQL has focused
almost exclusively on medical diseases, with little
attention given to psychiatric disorders. Studies
conducted with adults suggest that a range of psy-
chiatric disorders including schizophrenia, depres-
sion, bipolar mood disorder, and anxiety disorders
signiﬁcantly impair HRQL [73–76]. Furthermore,
clinical trials have found that treatment of these
psychiatric disorders can improve HRQL [77,78].
Despite the fact that mental health problems are
also common in children [79], little research has
examined the HRQL impact of psychiatric disor-
ders in pediatric populations.
The limited available data in this area suggest
that a range of psychiatric disorders have a signiﬁ-
cant negative impact on children’s HRQL [80]. Fur-
thermore, results of one clinical trial indicate that
treatment of attention-deﬁcit/hyperactivity disorder,
one example of a psychiatric disorder, can signiﬁ-
cantly improve psychosocial aspects of HRQL [81].
Given these initial ﬁndings, it is recommended that
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further research be conducted to examine the
impact of psychiatric disorders and treatment on
children’s HRQL.
Conclusions
The FDA and pharmaceutical companies have
recently demonstrated increasing awareness of the
need for additional understanding of drug treat-
ment effects among children. In the pediatric
health outcomes literature, there is growing con-
sensus that HRQL instruments are an essential
complement to clinical symptom measures in pro-
viding a comprehensive picture of children’s health
status. As more pediatric clinical trials have been
initiated, however, researchers have encountered
a unique set of challenges involved in assessing
HRQL among children, such as identifying the
age at which children can reliably report various
domains of HRQL and determining whether chil-
dren or their parents are the best respondents. Reli-
able and valid assessment of HRQL will require
thorough planning and instrument development,
including pilot testing and cognitive debrieﬁng.
Careful attention to the details of instrument devel-
opment and study design will lead to a greater
understanding of the broad impact of disease and
treatment among pediatric populations. The results
Table 2 Selected generic HRQL measures
Measure Reference
Reporter
(age group) Number of  items Subscales
Child Health and Illness
Proﬁle–Adolescent 
(CHIP–AE)
Starﬁeld et al. [55] Self  (11–17) 153 Satisfaction, Achievement, Disorders,
Risks, Discomfort, Resilience
Child Health
Questionnaire (CHQ)
Landgraf  et al. [56] Self  (10–19)
Parent (4–19)
87
Multiple versions
including: 28,
50, 98
Physical Functioning, Role/Social 
Emotional,* Role/Social Behavioral,* 
Role/Social Physical, Bodily Pain, General
Behavior, Mental Health, Self-Esteem, 
General Health Perceptions, Change in 
Health, Parental Impact-Emotional, 
Parental Impact-Time, Family Activities, 
Family Cohesion
Child Quality of  Life
Questionnaire (CQOL)
Graham et al. [57] Self  and Parent
(9–15)
15 Getting About and Using Hands, Out of  
School Activities, Friends, Family 
Relationships, Discomfort Due to Bodily 
Symptoms, Worries, Depression, Seeing, 
Communication, Eating, Sleep, Appearance
Functional Status
II-R (FSIIR)
Stein and Jessop [58] Parent (0–16) Multiple versions
including: 14 and
43
Communication, Mobility, Mood, Energy, 
Sleeping, Eating, Toileting, Play
KINDL (German generic
quality of  life instrument 
for children)
Ravens-Sieberer and
Bullinger [59]
Self  (8–16) 40 Mental, Physical, Social Life, Psychologic 
Well Being, Social Relationships, Physical 
Functioning, Everyday Life Activities
Pediatric Quality of  Life
Questionnaire (PedsQL)
Varni et al. [60] Child (8–12)
Adolescent
(13–18)
Parent (8–18)
15 items
comprising 3 core 
scales
30 additional
items comprising
8 modules
Physical Functioning, Psychologic 
Functioning Scale, Social Functioning 
Scale, Pain, Nausea, Procedural Anxiety, 
Treatment Anxiety, Worry, Cognitive 
Problems, Perceived Physical Appearance,
Physician/Nurse Communication
TNO-AZL Child Quality
of  Life Questionnaire 
(TACQOL)
Verrips et al. [61]
Vogels et al. [35]
Theunissen et al. [39]
Self  (8–15)
Parent (5–15)†
Parent (6–15)‡
56 Physical Complaints, Motor Functioning, 
Autonomous Functioning, Social 
Functioning, Cognitive Functioning, Positive 
Moods, Negative Moods
TNO-AZL Preschool
Children Quality of  Life 
Questionnaire 
(TAPQOL)
Fekkes et al. [62] Parent (1–5) 43 Physical Functioning (sleep, appetite, lung 
problems, stomach problems, skin 
problems, motor functioning), Social 
Functioning (problem behavior, social 
functioning), Cognitive Functioning 
(communication), Emotional Functioning 
(positive mood, anxiety, liveliness)
*These two scales are combined in the 28- and 50-item versions.
†Verrips et al. [61].
‡Vogels et al. [35].
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of this research can guide development of treat-
ments that will improve children’s HRQL.
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